When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Holdings, parent company of the pharmaceutical giant Novo Nordisk, is spending $16.5 billion on the acquisition. The ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

Shortly after unveiling a $400 million upgrade at its campus in Hillerød, Denmark, Novo Nordisk is reinforcing its commitment ...

The latest update is out from Novo Nordisk ( (NVO) ).

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...

The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.